Author:
Dorr Casey R., ,Wu Baolin,Remmel Rory P.,Muthusamy Amutha,Schladt David P.,Abrahante Juan E.,Guan Weihua,Mannon Roslyn B.,Matas Arthur J.,Oetting William S.,Jacobson Pamala A.,Israni Ajay K.
Funder
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,Genetics,Molecular Medicine
Reference82 articles.
1. Annual Data Report of the US Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR). Preface. Am J Transpl. 2013;13(Suppl 1): 1–7.
2. Endrenyi L, Tothfalusi L. Determination of bioequivalence for drugs with narrow therapeutic index: reduction of the regulatory burden. J Pharm Pharm Sci. 2013;16:676–82.
3. Gaynor JJ, Ciancio G, Guerra G, Sageshima J, Roth D, Goldstein MJ, et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transpl Int. 2016;29:216–26.
4. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation. 1996;62:900–5.
5. Lancia P, Jacqz-Aigrain E, Zhao W. Choosing the right dose of tacrolimus. Arch Dis Child. 2015;100:406–13.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献